echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA: The effect of diabetes-depression co-intervention on the improvement of clinical symptoms in patients with co-disease.

    JAMA: The effect of diabetes-depression co-intervention on the improvement of clinical symptoms in patients with co-disease.

    • Last Update: 2020-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Statistics have found that the increasing proportion of people with diabetes with mental health problems leads to a worsening of their prognostics and the inability of most patients to effectively intervene in mental health problems.
    recently examined the effects of diabetes-mental illness co-care patterns on depressive symptoms and cardiovascular metabolic indicators in adult diabetes patients with depression.
    study was conducted in India and recruited people with type 2 diabetes with a health questionnaire score of at least 10 points, hemoglobin A1c (HbA1c) at least 8%, systolic blood pressure (SBP) at least 140 mm Hg, or low density lipoprotein (LDL) cholesterol at least 130 mg/dL.
    randomly divided into joint intervention groups (n-196) or control groups (n-208), in which patients received 12 months of self-management support from non-physician care coordinators, electronic health records decision support to facilitate physician adjustment of treatment and expert case review, followed by follow-up for 12 months without intervention.
    patients received routine care for more than 24 months.
    results of the study showed a reduction of at least 50% in intergroup depressive symptom scale (SCL-20) score over 24 months (range 0-4; higher score indicates more severe symptoms), hbA1c decreased by at least 0.5%, SBP decreased by 5mmHg, and LDL cholesterol decreased by 10 mg/dL.
    -specified secondary endpoints are 12 and 24 months to meet treatment targets (HbA1c-lt;7.0%, SBP-lt;130 mm Hg, LDL Cholesterol-lt;100 mg/dL) or personal prognosiosal improvement (SCL-20 score drop of 50%, HbA1c decrease Percentage of patients with sBP reduction of 5mm Hg, LDL cholesterol reduction of 10mg/dL, percentage of patients with all HbA1c, SBP and LDL cholesterol indicators, SCL-20 score, patient health questionnaire-9 score, HbA1c, SBP and LLD cholesterol reduction on average.
    404 patients with an average age of 53 years, male 40.8 percent and 378 patients (93.5 percent) completed the trial.
    the proportion of patients who achieved the main results increased significantly (71.6% vs. 57.4%; difference: 16.9%) compared to the conventional care group.
    of the 16 pre-specified secondary results, there was no statistically significant difference between the groups of 10 results at 12 months and 13 results at 24 months.
    adverse events in the intervention and routine care groups include cardiovascular events or hospitalization (4 .2.0% vs. 7 .4 percent), stroke (0 vs. 3 .4 percent), death (2 .0 percent vs. 7 .4 percent), and severe hypoglycemia (8.4.1 percent vs. vs. 0.).
    study, for patients with diabetes and depression, co-intervention can significantly improve depressive symptoms and cardiovascular metabolic indicators at 24 months.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.